TELECOMS
30.7.2020 09:02:09 CEST | Business Wire | Press release
Developing Telecoms has participated in this week’s Huawei Better World Summit which explored the impact of COVID-19 globally, and examined how ICT and 5G technologies can minimize disruption and fight back against the virus while sustaining business operation.
MTN, one of Huawei’s partners at the summit, a pan-African and Middle East group headquartered in South Africa that delivers voice, data, digital and financial services to a customer base of +250 million, outlined its BRIGHT strategy comprising of 6 pillars including Best Network, Returns, Ignite Commercial Performance, Growth in Digital and Data, Hearts and Minds as well as Technology Excellence. This is helping MTN to achieve the goal of 300 million subscribers by 2022, 200 million of which will be data users, and 100 million digital services users.
During the summit, MTN’s Bernice Samuels showed how MTN recognized the onset of COVID-19 as an economic and humanitarian crisis in addition to a health crisis and was able to leverage its resources and footprint very quickly to provide help across its markets.
MTN introduced financial relief measures to support employees experiencing financial hardship, and work from home measures to continue operating the business and supporting its customers. All contact and call centres were furnished with work-from-home toolkits to keep service levels uninterrupted.
For customers, the focus was threefold:
- Communication around safety, prevention and preventing social stigmatization of people who were infected;
- Delivering relief by taking the form of like SMS or free allowances or traffic to educational institutions when they were closed, support for hospital staff, and free P2P money transfers;
- Support broader needs around the provision of vital supplies.
MTN also partnered with UNECA (United Nations Economic Commission in Africa) in June to enhance the ability of governments to undertake needs assessments measuring the efficacy of their communications, as well as to supplement and complement population screenings.
Digital is always spoken of as a disruptor, and the powerful shifts coming from digital are sometimes viewed as unsettling and chaotic. Developing Telecoms thinks the COVID-19 Pandemic has shown that this is wrong. Digital is not only a massive enabler to deliver convenience, safety, access, personalization and efficiency, digital can even help fight the crisis.
Developing Telecoms expects MTN will continue working with Huawei together to accelerate digital transformation capability, enabling their customers to enjoy the benefits of a modern connected digital life.
About Developing Telecoms
Developing Telecoms is the leading online news portal for telecoms in emerging markets, delivering telecommunications news and information for senior management and decision makers at network operators, governments and end users. Developing Telecoms receives 2.2 million yearly page views and gets over 760,000 yearly online visitors. Its weekly emerging markets newsletter has over 40,000 subscribers. Developing Telecoms publishes a range of special reports about telecoms in emerging markets spanning topics including 5G, IoT, Smart Cities and Last Mile Connectivity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200730005340/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom